The former site head of Bayer's Berkeley campus is taking over as CEO of Menlo Park-based Grail Inc., which has raised close to $2 billion to develop a simple blood test aimed at detecting cancer early.
Hans Bishop, who led pioneering cancer immunotherapy company Juno Therapeutics Inc. until its $9 billion sale in March 2018 to Celgene Corp. (NASDAQ: CELG), immediately took over for Jennifer Cook. He was at Bayer for three years until 2010 and the former Chiron Corp. in Emeryville for nearly four…
